Generic submissions under review
Notice to stakeholders
As of March 20, 2026, the downloadable Excel version of the list is now in a highlighted section for improved visibility and easier access.
How to access a list of generic drug submissions currently under review.
On this page
- About the generic submissions under review list
- Finding information on the list
- Decisions
- Access to generic drugs
- External consultations
- Other lists of submissions under review
- Contact us
- View the list
About the generic submissions under review list
The generic submissions under review (GSUR) list helps to make our review processes more transparent. The list will help Canadians understand if generic versions of brand name drugs are currently under review in Canada.
The GSUR list was announced as part of Phase III of the submissions under review (SUR) list initiative. A notice was published in 2024 announcing the expansion of the GSUR list.
The GSUR list includes abbreviated new drug submissions (ANDSs) accepted into review on or after October 1, 2018.
Finding information on the list
The GSUR list entries each include the:
- medicinal ingredient(s)
- therapeutic area populated with the World Health Organization Anatomical Therapeutic Chemical code
- year and month the submission was accepted into review
- company (sponsor) name for ANDSs accepted into review on or after April 1, 2024 only (for all other submissions, the information is listed as 'not available')
The list is updated monthly.
Decisions
Submissions are added to the GSUR list after they have been accepted into review. They remain on the GSUR list through interim negative decisions and various administrative and/or regulatory holds. For more information about the submission process and review targets, refer to the Guidance on management of drug submissions and applications.
A submission is removed from the GSUR list when:
- the submission is cancelled or
- a final decision is made
You can see if a submission has been approved in the Notice of compliance database.
Health Canada announced in August 2018 that it will publish regulatory decision summaries for final positive and negative decisions for certain prescription generic drug submissions that might be of interest to stakeholders. These can be found using the Regulatory Decision Summary search tool in the Drug and health product register.
Access to generic drugs
Many factors affect Canadians' access to generic drugs. For more information about generic drug products and submissions, see the fact sheet on access to generic drugs in Canada.
External consultations
Several external consultations have been held throughout the evolution of the SUR list initiative. In 2017, an external consultation was held on five transparency proposals for prescription drugs. This report provides a summary of the consultation results. An additional consultation was held in 2019 to assess the use of adding the company (sponsor) name to the GSUR list and the resulting impacts on stakeholders.
Other lists of submissions under review
The submissions under review (SUR) lists include new drug submissions and supplemental new drug submissions for new uses.
Learn more about the Drug and Health Products Submissions Under Review lists.
Contact us
Questions can be sent to us by email at opprs.enquiries-enquetes.bprse@hc-sc.gc.ca.
View the list
You can view the generic submissions under review list any time.
This list is current as of 2026-02-28.
Download the Excel version (XLSX format, 65 Kb)
| Medicinal Ingredient(s) | Company Name (available for submissions accepted into review on or after April 1, 2024) | Therapeutic Area | Year, Month Submission was Accepted into Review |
|---|---|---|---|
Abacavir sulfate, dolutegravir sodium, lamivudine |
Not available |
Antivirals for systemic use |
2021-04 |
Abacavir sulfate, dolutegravir sodium, lamivudine |
Not available |
Antivirals for systemic use |
2023-03 |
Abacavir sulfate, dolutegravir sodium, lamivudine |
Apotex Inc |
Antivirals for systemic use |
2024-08 |
Abacavir sulfate, dolutegravir sodium, lamivudine |
Pharmascience Inc |
Antivirals for systemic use |
2025-05 |
Abiraterone acetate |
Not available |
Endocrine therapy |
2023-10 |
Abiraterone acetate |
Marcan Pharmaceuticals Inc |
Endocrine therapy |
2026-02 |
Acalabrutinib maleate |
MSN Labs Canada Inc. |
Antineoplastic agents |
2025-12 |
Acetaminophen |
Atabay Kimya Sanayi VE Ticaret A.S-Manufacturer |
Analgesics |
2025-08 |
Acyclovir |
Not available |
Antivirals for systemic use |
2023-05 |
Acyclovir |
Zydus Lifesciences Limited |
Antibiotics and chemotherapy for dermatological use |
2024-12 |
Acyclovir |
JAMP Pharma Corporation |
Antibiotics and chemotherapy for dermatological use |
2025-05 |
Acyclovir |
Mint Pharmaceuticals Inc |
Antivirals for systemic use |
2025-11 |
Afatinib dimaleate |
Not available |
Antineoplastic agents |
2020-01 |
Alectinib hydrochloride |
Not available |
Antineoplastic agents |
2022-11 |
Allopurinol |
Pharmaris Canada Inc |
Antigout preparations |
2026-01 |
Amantadine hydrochloride |
Not available |
Anti-parkinson drugs |
2024-02 |
Ambrisentan |
Ambicare Pharmaceuticals Inc. |
Antihypertensives |
2025-06 |
Amiodarone hydrochloride |
JAMP Pharma Corporation |
Cardiac therapy |
2024-07 |
Amiodarone hydrochloride |
Formative Pharma Inc. |
Cardiac therapy |
2024-09 |
Amlodipine besylate |
Teva Canada Limited |
Calcium channel blockers |
2024-08 |
Amoxicillin trihydrate, clavulanate potassium |
Pharmaris Canada Inc |
Antibacterials for systemic use |
2025-06 |
Amoxicillin trihydrate, clavulanate potassium |
Pharmaris Canada Inc |
Antibacterials for systemic use |
2025-06 |
Amphotericin B |
Marcan Pharmaceuticals Inc |
Antimycotics for systemic use |
2024-07 |
Apalutamide |
Sandoz Canada Incorporated |
Endocrine therapy |
2025-01 |
Apalutamide |
Lupin Pharma Canada Limited |
Endocrine therapy |
2025-01 |
Apalutamide |
Sandoz Canada Incorporated |
Endocrine therapy |
2026-02 |
Apixaban |
Not available |
Antithrombotic agents |
2023-06 |
Apixaban |
MSN Labs Canada Inc. |
Antithrombotic agents |
2025-08 |
Apixaban |
Devatis Canada Inc. |
Antithrombotic agents |
2026-02 |
Apremilast |
Not available |
Immunosuppressants |
2024-03 |
Apremilast |
Mint Pharmaceuticals Inc |
Immunosuppressants |
2024-09 |
Aprepitant |
Not available |
Antiemetics and antinauseants |
2023-01 |
Aprepitant |
JAMP Pharma Corporation |
Antiemetics and antinauseants |
2026-02 |
Aripiprazole |
Not available |
Psycholeptics |
2023-12 |
Aripiprazole |
Taro Pharmaceuticals Inc |
Psycholeptics |
2024-08 |
Aripiprazole |
Sandoz Canada Incorporated |
Psycholeptics |
2025-01 |
Aripiprazole |
Sterimax Inc |
Psycholeptics |
2025-07 |
Atomoxetine hydrochloride |
Not available |
Psychoanaleptics |
2024-02 |
Atovaquone |
Not available |
Antiprotozoals |
2023-04 |
Axitinib |
Not available |
Antineoplastic agents |
2024-02 |
Azithromycin dihydrate |
Zydus Lifesciences Limited |
Antibacterials for systemic use |
2025-04 |
Benserazide hydrochloride, levodopa |
Mint Pharmaceuticals Inc |
Anti-parkinson drugs |
2025-08 |
Betamethasone dipropionate, calcipotriol monohydrate |
Glenmark Pharmaceuticals Canada Inc. |
Antipsoriatics |
2026-02 |
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate |
JAMP Pharma Corporation |
Antivirals for systemic use |
2024-08 |
Bictegravir sodium, emtricitabine, tenofovir alafenamide fumarate |
Lupin Pharma Canada Limited |
Antivirals for systemic use |
2025-07 |
Bilastine |
Not available |
Antihistamines for systemic use |
2023-12 |
Bilastine |
Not available |
Antihistamines for systemic use |
2024-02 |
Bilastine |
Laboratoire Riva Inc |
Antihistamines for systemic use |
2024-07 |
Bilastine |
Mint Pharmaceuticals Inc |
Antihistamines for systemic use |
2025-01 |
Bilastine |
MSN Labs Canada Inc. |
Antihistamines for systemic use |
2025-03 |
Bimatoprost |
Not available |
Ophthalmologicals |
2022-02 |
Bimatoprost |
Not available |
Ophthalmologicals |
2023-06 |
Bimatoprost |
Not available |
Ophthalmologicals |
2023-07 |
Bimatoprost |
JAMP Pharma Corporation |
Ophthalmologicals |
2024-11 |
Bimatoprost |
JAMP Pharma Corporation |
Ophthalmologicals |
2025-07 |
Bisoprolol fumarate |
Nora Pharma Inc |
Beta blocking agents |
2025-02 |
Bisoprolol fumarate |
Pharmaris Canada Inc |
Beta blocking agents |
2026-02 |
Bleomycin sulfate |
Marcan Pharmaceuticals Inc |
Antineoplastic agents |
2025-09 |
Bleomycin sulfate |
Juno Pharma Canada Inc. |
Antineoplastic agents |
2025-09 |
Bortezomib |
Not available |
Antineoplastic agents |
2023-07 |
Bosutinib |
Taro Pharmaceuticals Inc |
Antineoplastic agents |
2024-10 |
Brexpiprazole |
Not available |
Psycholeptics |
2023-04 |
Brexpiprazole |
Not available |
Psycholeptics |
2023-04 |
Brexpiprazole |
Not available |
Psycholeptics |
2023-04 |
Brexpiprazole |
Not available |
Psycholeptics |
2023-04 |
Brexpiprazole |
Not available |
Psycholeptics |
2023-05 |
Brexpiprazole |
Zydus Lifesciences Limited |
Psycholeptics |
2025-02 |
Brexpiprazole |
Mint Pharmaceuticals Inc |
Psycholeptics |
2025-04 |
Brexpiprazole |
Marcan Pharmaceuticals Inc |
Psycholeptics |
2025-05 |
Brimonidine tartrate |
Angita Pharma Inc |
Ophthalmologicals |
2024-11 |
Brimonidine tartrate, timolol maleate |
Not available |
Ophthalmologicals |
2023-07 |
Brimonidine tartrate, timolol maleate |
Devatis Canada Inc. |
Ophthalmologicals |
2026-01 |
Brivaracetam |
Not available |
Antiepileptics |
2023-11 |
Brivaracetam |
Pharmascience Inc |
Antiepileptics |
2024-09 |
Brivaracetam |
Glenmark Pharmaceuticals Canada Inc. |
Antiepileptics |
2024-12 |
Brivaracetam |
JAMP Pharma Corporation |
Antiepileptics |
2025-05 |
Bromfenac sodium sesquihydrate |
Lupin Pharma Canada Limited |
Ophthalmologicals |
2025-04 |
Bromfenac sodium sesquihydrate |
Laboratoire Riva Inc |
Ophthalmologicals |
2025-12 |
Buffer solution, melphalan hydrochloride |
Not available |
Antineoplastic agents |
2022-02 |
Bupivacaine hydrochloride |
Not available |
Anesthetics |
2024-02 |
Bupivacaine hydrochloride |
Formative Pharma Inc. |
Anesthetics |
2025-10 |
Bupivacaine hydrochloride |
Formative Pharma Inc. |
Anesthetics |
2025-10 |
Buprenorphine |
Not available |
Analgesics |
2024-01 |
Buprenorphine hydrochloride, naloxone hydrochloride |
Hikma Canada Limited |
Other nervous system drugs |
2025-06 |
Bupropion hydrochloride |
Not available |
Psychoanaleptics |
2021-07 |
Bupropion hydrochloride |
Not available |
Psychoanaleptics |
2023-04 |
Bupropion hydrochloride |
Pharmascience Inc |
Psychoanaleptics |
2024-07 |
Bupropion hydrochloride |
Lupin Pharma Canada Limited |
Psychoanaleptics |
2025-01 |
Cabergoline |
Mantra Pharma Inc. |
Other gynecologicals |
2024-10 |
Cabozantinib malate |
Taro Pharmaceuticals Inc |
Antineoplastic agents |
2024-12 |
Cabozantinib malate |
Teva Canada Limited |
Antineoplastic agents |
2024-12 |
Calcitriol |
Not available |
Vitamins |
2023-05 |
Canagliflozin |
Not available |
Drugs used in diabetes |
2023-12 |
Canagliflozin |
MSN Labs Canada Inc. |
Drugs used in diabetes |
2025-08 |
Cannabidiol |
Apotex Inc |
Antiepileptics |
2025-05 |
Carbamazepine |
Auro Pharma Inc |
Antiepileptics |
2024-10 |
Carbamazepine |
Auro Pharma Inc |
Antiepileptics |
2024-12 |
Carbamazepine |
Mint Pharmaceuticals Inc |
Antiepileptics |
2026-01 |
Carbidopa, levodopa |
Not available |
Anti-parkinson drugs |
2023-09 |
Carbidopa, levodopa |
Pharmascience Inc |
Anti-parkinson drugs |
2025-10 |
Carboplatin |
Hikma Canada Limited |
Antineoplastic agents |
2026-01 |
Carboplatin |
Marcan Pharmaceuticals Inc |
Antineoplastic agents |
2026-01 |
Carfilzomib |
Not available |
Antineoplastic agents |
2022-03 |
Carfilzomib |
Not available |
Antineoplastic agents |
2022-05 |
Carfilzomib |
Not available |
Antineoplastic agents |
2022-06 |
Carfilzomib |
Not available |
Antineoplastic agents |
2022-09 |
Carfilzomib |
Not available |
Antineoplastic agents |
2023-06 |
Carfilzomib |
Glenmark Pharmaceuticals Canada Inc. |
Antineoplastic agents |
2024-07 |
Carfilzomib |
Juno Pharma Canada Inc. |
Antineoplastic agents |
2025-07 |
Cefixime |
Not available |
Antibacterials for systemic use |
2023-09 |
Cefixime |
Not available |
Antibacterials for systemic use |
2023-10 |
Cefixime |
JAMP Pharma Corporation |
Antibacterials for systemic use |
2026-01 |
Ceftazidime |
Hikma Canada Limited |
Antibacterials for systemic use |
2026-02 |
Celecoxib |
Not available |
Antiinflammatory and antirheumatic products |
2019-04 |
Ciclesonide |
Glenmark Pharmaceuticals Canada Inc. |
Drugs for obstructive airway diseases |
2024-12 |
Ciclopirox |
Not available |
Antifungals for dermatological use |
2023-04 |
Ciprofloxacin hydrochloride |
JAMP Pharma Corporation |
Antibacterials for systemic use |
2025-05 |
Citalopram hydrobromide |
Marcan Pharmaceuticals Inc |
Psychoanaleptics |
2025-11 |
Cladribine |
Not available |
Immunosuppressants |
2024-01 |
Clindamycin phosphate |
Hikma Canada Limited |
Antibacterials for systemic use |
2024-09 |
Clofarabine |
Marcan Pharmaceuticals Inc |
Antineoplastic agents |
2024-12 |
Clonazepam |
JAMP Pharma Corporation |
Antiepileptics |
2025-12 |
Clonidine hydrochloride |
JAMP Pharma Corporation |
Antihypertensives |
2024-05 |
Clonidine hydrochloride |
Mint Pharmaceuticals Inc |
Antihypertensives |
2024-08 |
Clonidine hydrochloride |
Auro Pharma Inc |
Antihypertensives |
2025-12 |
Clopidogrel bisulfate |
Not available |
Antithrombotic agents |
2023-03 |
Cobicistat, elvitegravir, emtricitabine, tenofovir alafenamide |
Not available |
Antivirals for systemic use |
2023-09 |
Colesevelam hydrochloride |
Not available |
Lipid modifying agents |
2021-05 |
Colesevelam hydrochloride |
JAMP Pharma Corporation |
Lipid modifying agents |
2024-06 |
Cyclophosphamide |
Accord Healthcare Inc |
Antineoplastic agents |
2025-10 |
Cyclophosphamide monohydrate |
Formative Pharma Inc. |
Antineoplastic agents |
2024-04 |
Cyclosporine |
Auro Pharma Inc |
Immunosuppressants |
2025-07 |
Dabigatran etexilate mesilate |
Auro Pharma Inc |
Antithrombotic agents |
2024-05 |
Dabigatran etexilate mesilate |
Sandoz Canada Incorporated |
Antithrombotic agents |
2024-12 |
Dabigatran etexilate mesilate |
Pharmaris Canada Inc |
Antithrombotic agents |
2025-08 |
Dacarbazine |
Sterimax Inc |
Antineoplastic agents |
2024-08 |
Dalbavancin hydrochloride |
Hikma Canada Limited |
Antibacterials for systemic use |
2025-02 |
Dapagliflozin |
Pharmaris Canada Inc |
Drugs used in diabetes |
2025-02 |
Dapagliflozin |
MSN Labs Canada Inc. |
Drugs used in diabetes |
2025-05 |
Dapsone |
Avir Pharma Inc |
Anti-acne preparations |
2025-12 |
Daptomycin |
Biocon Pharma Limited |
Antibacterials for systemic use |
2025-07 |
Dasatinib |
Not available |
Antineoplastic agents |
2022-05 |
Dasatinib monohydrate |
Eugia Pharma Inc. |
Antineoplastic agents |
2024-05 |
Degarelix acetate |
Not available |
Endocrine therapy |
2024-01 |
Desmopressin acetate |
Odan Laboratories Ltd |
Pituitary and hypothalamic hormones and analogues |
2025-02 |
Desvenlafaxine succinate |
Mint Pharmaceuticals Inc |
Psychoanaleptics |
2024-04 |
Desvenlafaxine succinate |
Rubicon Research Canada Limited |
Psychoanaleptics |
2025-06 |
Dexamethasone, tobramycin |
JAMP Pharma Corporation |
Ophthalmologicals |
2024-12 |
Dexlansoprazole |
Sandoz Canada Incorporated |
Drugs for acid related disorders |
2024-05 |
Dexmedetomidine hydrochloride |
Not available |
Psycholeptics |
2022-09 |
Dexmedetomidine hydrochloride |
Juno Pharma Canada Inc. |
Psycholeptics |
2025-08 |
Dextroamphetamine sulfate |
Waymade Canada Inc. |
Psychoanaleptics |
2025-03 |
Dextroamphetamine sulfate |
Pharmascience Inc |
Psychoanaleptics |
2025-09 |
Diclofenac potassium |
Not available |
Antiinflammatory and antirheumatic products |
2024-02 |
Diclofenac potassium |
JAMP Pharma Corporation |
Antiinflammatory and antirheumatic products |
2024-07 |
Diclofenac potassium |
Laboratoire Riva Inc |
Antiinflammatory and antirheumatic products |
2025-01 |
Diclofenac potassium |
Mint Pharmaceuticals Inc |
Antiinflammatory and antirheumatic products |
2025-07 |
Digoxin |
Juno Pharma Canada Inc. |
Cardiac therapy |
2025-08 |
Diltiazem hydrochloride |
Not available |
Calcium channel blockers |
2024-02 |
Dipyridamole |
Juno Pharma Canada Inc. |
Antithrombotic agents |
2025-12 |
Dobutamine hydrochloride |
Not available |
Cardiac therapy |
2024-03 |
Dolutegravir |
Not available |
Antivirals for systemic use |
2020-01 |
Dolutegravir sodium |
Not available |
Antivirals for systemic use |
2023-09 |
Donepezil hydrochloride monohydrate |
Not available |
Psychoanaleptics |
2023-08 |
Dorzolamide hydrochloride, timolol maleate |
JAMP Pharma Corporation |
Ophthalmologicals |
2025-05 |
Doxepin hydrochloride |
Not available |
Psychoanaleptics |
2023-12 |
Doxepin hydrochloride |
Taro Pharmaceuticals Inc |
Psychoanaleptics |
2025-08 |
Doxorubicin hydrochloride |
Accord Healthcare Inc |
Antineoplastic agents |
2024-05 |
Doxycycline hyclate |
Ambicare Pharmaceuticals Inc. |
Antibacterials for systemic use |
2026-02 |
Doxycycline monohydrate |
Not available |
Antibacterials for systemic use |
2022-12 |
Doxylamine succinate, pyridoxine hydrochloride |
Not available |
Antihistamines for systemic use |
2023-09 |
Dronedarone hydrochloride |
Odan Laboratories Ltd |
Cardiac therapy |
2025-07 |
Edaravone |
Sandoz Canada Incorporated |
Other nervous system drugs |
2025-11 |
Edoxaban tosylate |
Mint Pharmaceuticals Inc |
Antithrombotic agents |
2025-11 |
Edoxaban tosylate |
Laboratoire Riva Inc |
Antithrombotic agents |
2026-02 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2019-11 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2020-01 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2020-02 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2020-11 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2020-12 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2021-04 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2022-03 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2022-06 |
Efinaconazole |
Not available |
Antifungals for dermatological use |
2023-05 |
Elagolix sodium |
JAMP Pharma Corporation |
Pituitary and hypothalamic hormones and analogues |
2025-05 |
Eltrombopag olamine |
Not available |
Antihemorrhagics |
2023-09 |
Eltrombopag olamine |
Not available |
Antihemorrhagics |
2024-02 |
Eltrombopag olamine |
Dr Reddys Laboratories Ltd |
Antihemorrhagics |
2024-04 |
Eltrombopag olamine |
Auro Pharma Inc |
Antihemorrhagics |
2025-07 |
Eltrombopag olamine |
Mint Pharmaceuticals Inc |
Antihemorrhagics |
2026-01 |
Eltrombopag olamine |
Devatis Canada Inc. |
Antihemorrhagics |
2026-02 |
Eluxadoline |
Zydus Lifesciences Limited |
Antidiarrheals, intestinal anti-inflammatory/anti-infective agents |
2025-08 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2021-09 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2021-10 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2021-11 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2022-09 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2022-09 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2023-04 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2023-05 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2023-12 |
Empagliflozin |
Not available |
Drugs used in diabetes |
2024-02 |
Empagliflozin |
Laboratoire Riva Inc |
Drugs used in diabetes |
2024-10 |
Empagliflozin |
Mantra Pharma Inc. |
Drugs used in diabetes |
2025-01 |
Empagliflozin |
Dr Reddys Laboratories Ltd |
Drugs used in diabetes |
2025-03 |
Empagliflozin |
Alembic Pharmaceuticals Limited |
Drugs used in diabetes |
2025-03 |
Empagliflozin |
Sandoz Canada Incorporated |
Drugs used in diabetes |
2025-12 |
Empagliflozin |
Zydus Lifesciences Limited |
Drugs used in diabetes |
2026-01 |
Empagliflozin |
Devatis Canada Inc. |
Drugs used in diabetes |
2026-02 |
Empagliflozin, metformin hydrochloride |
Not available |
Drugs used in diabetes |
2021-10 |
Empagliflozin, metformin hydrochloride |
JAMP Pharma Corporation |
Drugs used in diabetes |
2025-03 |
Empagliflozin, metformin hydrochloride |
Pharmascience Inc |
Drugs used in diabetes |
2025-09 |
Emtricitabine, rilpivirine hydrochloride, tenofovir alafenamide hemifumarate |
Not available |
Antivirals for systemic use |
2022-04 |
Emtricitabine, tenofovir alafenamide |
Not available |
Antivirals for systemic use |
2022-01 |
Emtricitabine, tenofovir alafenamide fumarate |
Not available |
Antivirals for systemic use |
2022-04 |
Emtricitabine, tenofovir alafenamide hemifumarate |
Not available |
Antivirals for systemic use |
2022-04 |
Emtricitabine, tenofovir alafenamide hemifumarate |
Not available |
Antivirals for systemic use |
2022-07 |
Entacapone |
Jamp Pharma Corporation |
Anti-parkinson drugs |
2025-11 |
Enzalutamide |
Not available |
Endocrine therapy |
2019-06 |
Enzalutamide |
Not available |
Endocrine therapy |
2022-04 |
Enzalutamide |
Dr Reddys Laboratories Ltd |
Endocrine therapy |
2024-09 |
Enzalutamide |
Apotex Inc |
Endocrine therapy |
2025-04 |
Enzalutamide |
Marcan Pharmaceuticals Inc |
Endocrine therapy |
2025-07 |
Enzalutamide |
Zydus Lifesciences Limited |
Endocrine therapy |
2025-09 |
Enzalutamide |
Pharmascience Inc |
Endocrine therapy |
2025-11 |
Eplerenone |
Not available |
Diuretics |
2023-07 |
Eribulin mesylate |
Not available |
Antineoplastic agents |
2023-07 |
Esomeprazole magnesium trihydrate, naproxen |
Not available |
Antiinflammatory and antirheumatic products |
2023-12 |
Esomeprazole, naproxen |
Pharmascience Inc |
Antiinflammatory and antirheumatic products |
2025-07 |
Estradiol hemihydrate |
Sun Pharma Canada Inc |
Sex hormones and modulators of the genital system |
2026-02 |
Estradiol hemihydrate, norethindrone acetate |
Novast Laboratories Ltd. |
Sex hormones and modulators of the genital system |
2025-08 |
Ethinyl estradiol, etonogestrel |
Searchlight Pharma Inc |
Other gynecologicals |
2025-12 |
Ethinyl estradiol, norethindrone acetate |
Apotex Inc |
Sex hormones and modulators of the genital system |
2024-05 |
Ethinyl estradiol, norethindrone acetate |
Lupin Pharma Canada Limited |
Sex hormones and modulators of the genital system |
2024-08 |
Ethinyl estradiol, norgestimate |
Lupin Pharma Canada Limited |
Sex hormones and modulators of the genital system |
2024-06 |
Famotidine |
Hikma Canada Limited |
Drugs for acid related disorders |
2025-10 |
Fampridine |
Auro Pharma Inc |
Other nervous system drugs |
2024-06 |
Felodipine |
Pharmaris Canada Inc |
Calcium channel blockers |
2025-12 |
Fenofibrate |
JAMP Pharma Corporation |
Lipid modifying agents |
2025-01 |
Fentanyl citrate |
Juno Pharmaceuticals Corp. |
Anesthetics |
2025-05 |
Fentanyl citrate |
Sterinova Inc |
Anesthetics |
2026-01 |
Fesoterodine fumarate |
Not available |
Urologicals |
2024-01 |
Fingolimod hydrochloride |
Not available |
Immunosuppressants |
2019-06 |
Fluconazole |
Not available |
Antimycotics for systemic use |
2023-05 |
Fludrocortisone 21-acetate |
Mint Pharmaceuticals Inc |
Corticosteroids for systemic use |
2024-05 |
Fludrocortisone 21-acetate |
Marcan Pharmaceuticals Inc |
Corticosteroids for systemic use |
2024-08 |
Fluticasone propionate |
Hikma Canada Limited |
Nasal preparations |
2024-09 |
Fluticasone propionate, salmeterol xinafoate |
Hikma Canada Limited |
Drugs for obstructive airway diseases |
2025-03 |
Formoterol fumarate dihydrate, mometasone furoate |
Lupin Pharma Canada Limited |
Drugs for obstructive airway diseases |
2024-05 |
Fosfomycin |
Not available |
Antibacterials for systemic use |
2023-08 |
Fosfomycin tromethamine |
Laboratoire Riva Inc |
Antibacterials for systemic use |
2025-03 |
Fosfomycin tromethamine |
Juno Pharmaceuticals Corp. |
Antibacterials for systemic use |
2025-06 |
Fulvestrant |
Not available |
Endocrine therapy |
2024-03 |
Furosemide |
JAMP Pharma Corporation |
Diuretics |
2025-05 |
Galantamine hydrobromide |
Not available |
Psychoanaleptics |
2023-08 |
Ganirelix acetate |
Not available |
Pituitary and hypothalamic hormones and analogues |
2024-02 |
Ganirelix acetate |
Sun Pharma Canada Inc |
Pituitary and hypothalamic hormones and analogues |
2024-05 |
Ganirelix acetate |
Pharmascience Inc |
Pituitary and hypothalamic hormones and analogues |
2025-10 |
Glatiramer acetate |
Not available |
Immunostimulants |
2020-11 |
Glycopyrrolate |
Hikma Canada Limited |
Drugs for functional gastrointestinal disorders |
2025-01 |
Glycopyrronium bromide |
Marcan Pharmaceuticals Inc |
Drugs for functional gastrointestinal disorders |
2025-12 |
Guanfacine hydrochloride |
Not available |
Antihypertensives |
2023-09 |
Haloperidol decanoate |
Formative Pharma Inc. |
Psycholeptics |
2025-05 |
Hydrochlorothiazide, olmesartan medoxomil |
JAMP Pharma Corporation |
Agents acting on the renin-angiotensin system |
2025-12 |
Hydromorphone hydrochloride |
Not available |
Analgesics |
2022-09 |
Hydromorphone hydrochloride |
Pharmascience Inc |
Analgesics |
2024-04 |
Hydroxychloroquine sulfate |
Not available |
Antiprotozoals |
2023-06 |
Hyoscine butylbromide |
Not available |
Drugs for functional gastrointestinal disorders |
2023-03 |
Ibrutinib |
Not available |
Antineoplastic agents |
2021-01 |
Ibrutinib |
Not available |
Antineoplastic agents |
2021-05 |
Ibrutinib |
Not available |
Antineoplastic agents |
2021-06 |
Ibrutinib |
Not available |
Antineoplastic agents |
2022-11 |
Indapamide |
Not available |
Diuretics |
2023-05 |
Indapamide, perindopril tert-butylamine salt |
Auro Pharma Inc |
Agents acting on the renin-angiotensin system |
2025-11 |
Iron (III)-hydroxide sucrose complex |
Not available |
Antianemic preparations |
2024-01 |
Isavuconazonium sulfate |
Ambicare Pharmaceuticals Inc. |
Antimycotics for systemic use |
2025-12 |
Ivabradine hydrochloride |
Pharmascience Inc |
Cardiac therapy |
2025-05 |
Ivabradine hydrochloride |
Mint Pharmaceuticals Inc |
Cardiac therapy |
2026-01 |
Ivacaftor |
Sandoz Canada Incorporated |
Other respiratory system products |
2024-11 |
Ivacaftor |
JAMP Pharma Corporation |
Other respiratory system products |
2026-02 |
Ivermectin |
Zydus Lifesciences Limited |
Other dermatological preparations |
2024-08 |
Ketamine hydrochloride |
Hikma Canada Limited |
Anesthetics |
2025-02 |
Ketamine hydrochloride |
Juno Pharmaceuticals Corp. |
Anesthetics |
2025-05 |
Ketorolac tromethamine |
Ambicare Pharmaceuticals Inc. |
Antiinflammatory and antirheumatic products |
2024-05 |
Labetalol hydrochloride |
Zydus Lifesciences Limited |
Beta blocking agents |
2025-04 |
Lacosamide |
Eugia Pharma Inc. |
Antiepileptics |
2024-06 |
Lacosamide |
Formative Pharma Inc. |
Antiepileptics |
2024-10 |
Lamotrigine |
Not available |
Antiepileptics |
2023-10 |
Lansoprazole |
Not available |
Drugs for acid related disorders |
2023-11 |
Lansoprazole |
JAMP Pharma Corporation |
Drugs for acid related disorders |
2026-02 |
Latanoprostene bunod |
Apotex Inc |
Ophthalmologicals |
2025-05 |
Leflunomide |
Not available |
Immunosuppressants |
2023-08 |
Lenvatinib mesylate |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2024-05 |
Letermovir |
Not available |
Antivirals for systemic use |
2024-02 |
Letrozole |
Sandoz Canada Incorporated |
Endocrine therapy |
2025-07 |
Levetiracetam |
Not available |
Antiepileptics |
2023-01 |
Levetiracetam |
Not available |
Antiepileptics |
2023-10 |
Levetiracetam |
Marcan Pharmaceuticals Inc |
Antiepileptics |
2024-04 |
Levetiracetam |
JAMP Pharma Corporation |
Antiepileptics |
2024-05 |
Levetiracetam |
Auro Pharma Inc |
Antiepileptics |
2025-03 |
Levetiracetam |
Fresenius Kabi Canada Ltd |
Antiepileptics |
2025-05 |
Levocarnitine |
Sterimax Inc |
Other alimentary tract and metabolism products |
2025-12 |
Levofloxacin hemihydrate |
Juno Pharmaceuticals Corp. |
Antibacterials for systemic use |
2025-01 |
Levothyroxine sodium |
Not available |
Thyroid therapy |
2023-11 |
Lidocaine, prilocaine |
Not available |
Antipruritics, including antihistamines, anesthetics, etc. |
2022-02 |
Lifitegrast |
Micro Labs Limited |
Ophthalmologicals |
2024-05 |
Linagliptin |
Not available |
Drugs used in diabetes |
2020-01 |
Linagliptin |
Not available |
Drugs used in diabetes |
2020-10 |
Linagliptin |
Not available |
Drugs used in diabetes |
2021-09 |
Linagliptin |
Not available |
Drugs used in diabetes |
2022-05 |
Linagliptin |
Not available |
Drugs used in diabetes |
2022-05 |
Linagliptin |
Not available |
Drugs used in diabetes |
2023-01 |
Linagliptin |
Not available |
Drugs used in diabetes |
2023-06 |
Linagliptin |
Not available |
Drugs used in diabetes |
2023-08 |
Linagliptin |
Not available |
Drugs used in diabetes |
2023-10 |
Linagliptin |
Ambicare Pharmaceuticals Inc. |
Drugs used in diabetes |
2025-01 |
Linagliptin |
Mantra Pharma Inc. |
Drugs used in diabetes |
2025-10 |
Linagliptin |
Zydus Lifesciences Limited |
Drugs used in diabetes |
2025-12 |
Linagliptin, metformin hydrochloride |
Not available |
Drugs used in diabetes |
2021-10 |
Linagliptin, metformin hydrochloride |
Not available |
Drugs used in diabetes |
2023-09 |
Linagliptin, metformin hydrochloride |
Not available |
Drugs used in diabetes |
2024-01 |
Linagliptin, metformin hydrochloride |
Dr Reddys Laboratories Ltd |
Drugs used in diabetes |
2025-04 |
Linagliptin, metformin hydrochloride |
Zydus Lifesciences Limited |
Drugs used in diabetes |
2026-02 |
Linezolid |
Glenmark Pharmaceuticals Canada Inc. |
Antibacterials for systemic use |
2025-02 |
Liothyronine sodium |
Not available |
Thyroid therapy |
2023-05 |
Liothyronine sodium |
Taro Pharmaceuticals Inc |
Thyroid therapy |
2024-06 |
Liothyronine sodium |
Accord Healthcare Inc |
Thyroid therapy |
2024-11 |
Liraglutide |
Biocon Pharma Limited |
Drugs used in diabetes |
2024-08 |
Liraglutide |
Biocon Pharma Limited |
Drugs used in diabetes |
2024-08 |
Liraglutide |
Dr Reddys Laboratories Ltd |
Drugs used in diabetes |
2024-12 |
Liraglutide |
Dr Reddys Laboratories Ltd |
Drugs used in diabetes |
2024-12 |
Liraglutide |
Zydus Lifesciences Limited |
Drugs used in diabetes |
2025-08 |
Liraglutide |
Teva Canada Limited |
Drugs used in diabetes |
2025-10 |
Liraglutide |
Zydus Lifesciences Limited |
Drugs used in diabetes |
2025-11 |
Liraglutide |
JAMP Pharma Corporation |
Drugs used in diabetes |
2026-02 |
Lorazepam |
Juno Pharmaceuticals Corp. |
Psycholeptics |
2024-08 |
Loxapine succinate |
JAMP Pharma Corporation |
Psycholeptics |
2025-05 |
Lurasidone hydrochloride |
Mint Pharmaceuticals Inc |
Psycholeptics |
2024-12 |
Macitentan |
Not available |
Antihypertensives |
2020-01 |
Macitentan |
Not available |
Antihypertensives |
2020-02 |
Macitentan |
Not available |
Antihypertensives |
2020-06 |
Macitentan |
Not available |
Antihypertensives |
2021-11 |
Macitentan |
Not available |
Antihypertensives |
2021-12 |
Macitentan |
Not available |
Antihypertensives |
2022-01 |
Macitentan |
Pharmascience Inc |
Antihypertensives |
2024-09 |
Macitentan |
Auro Pharma Inc |
Antihypertensives |
2024-12 |
Macitentan |
Ambicare Pharmaceuticals Inc. |
Antihypertensives |
2025-10 |
Medroxyprogesterone acetate |
Accord Healthcare Inc |
Sex hormones and modulators of the genital system |
2024-07 |
Medroxyprogesterone acetate |
Sterimax Inc |
Sex hormones and modulators of the genital system |
2025-04 |
Melphalan hydrochloride |
Not available |
Antineoplastic agents |
2024-03 |
Metformin hydrochloride |
Glenmark Pharmaceuticals Canada Inc. |
Drugs used in diabetes |
2024-05 |
Metformin hydrochloride |
Lupin Pharma Canada Limited |
Drugs used in diabetes |
2024-11 |
Metformin hydrochloride, sitagliptin phosphate |
Auro Pharma Inc |
Drugs used in diabetes |
2025-06 |
Metformin hydrochloride, sitagliptin phosphate monohydrate |
Not available |
Drugs used in diabetes |
2022-12 |
Metformin hydrochloride, sitagliptin phosphate monohydrate |
Laboratoire Riva Inc |
Drugs used in diabetes |
2025-07 |
Methadone hydrochloride |
Pharmascience Inc |
Other nervous system drugs |
2024-05 |
Methylprednisolone acetate |
Sterimax Inc |
Corticosteroids for systemic use |
2024-12 |
Metronidazole |
Taro Pharmaceuticals Inc |
Antibiotics and chemotherapy for dermatological use |
2024-08 |
Metronidazole |
JAMP Pharma Corporation |
Antibiotics and chemotherapy for dermatological use |
2025-05 |
Metronidazole |
Avir Pharma Inc |
Antibiotics and chemotherapy for dermatological use |
2025-10 |
Micafungin sodium |
Biocon Pharma Limited |
Antimycotics for systemic use |
2025-11 |
Midazolam |
Sterimax Inc |
Psycholeptics |
2024-08 |
Midodrine hydrochloride |
Mint Pharmaceuticals Inc |
Cardiac therapy |
2024-12 |
Mifepristone, misoprostol |
JAMP Pharma Corporation |
Sex hormones and modulators of the genital system |
2024-09 |
Miglustat |
Waymade Canada Inc. |
Other alimentary tract and metabolism products |
2024-08 |
Mirabegron |
Mint Pharmaceuticals Inc |
Urologicals |
2025-08 |
Mirabegron |
MSN Labs Canada Inc. |
Urologicals |
2025-09 |
Mirabegron |
Zydus Lifesciences Limited |
Urologicals |
2025-11 |
Mirtazapine |
Not available |
Psychoanaleptics |
2023-10 |
Mitomycin |
Formative Pharma Inc. |
Antineoplastic agents |
2026-02 |
Montelukast sodium |
Nora Pharma Inc |
Drugs for obstructive airway diseases |
2026-01 |
Moxifloxacin hydrochloride |
Not available |
Ophthalmologicals |
2023-07 |
Mycophenolate mofetil |
JAMP Pharma Corporation |
Immunosuppressants |
2024-06 |
Mycophenolic acid |
Auro Pharma Inc |
Immunosuppressants |
2024-05 |
Nadolol |
Not available |
Beta blocking agents |
2021-11 |
Naloxegol |
Not available |
Drugs for constipation |
2021-08 |
Naloxone hydrochloride |
Rubicon Research Canada Limited |
All other therapeutic products |
2025-04 |
Naloxone hydrochloride dihydrate |
Not available |
All other therapeutic products |
2022-10 |
Naloxone hydrochloride dihydrate |
Padagis Israel Pharmaceuticals Ltd |
All other therapeutic products |
2025-03 |
Naloxone hydrochloride dihydrate |
Juno Pharmaceuticals Corp. |
All other therapeutic products |
2025-08 |
Naltrexone hydrochloride |
Angita Pharma Inc |
Other nervous system drugs |
2026-02 |
Naproxen |
Auro Pharma Inc |
Antiinflammatory and antirheumatic products |
2025-01 |
Naproxen |
JAMP Pharma Corporation |
Antiinflammatory and antirheumatic products |
2025-06 |
Naproxen sodium, sumatriptan succinate |
JAMP Pharma Corporation |
Analgesics |
2025-08 |
Naratriptan hydrochloride |
Not available |
Analgesics |
2023-07 |
Nilotinib hydrochloride monohydrate |
Natco Pharma (Canada) Inc |
Antineoplastic agents |
2025-07 |
Nilotinib hydrochloride sesquihydrate |
MSN Labs Canada Inc. |
Antineoplastic agents |
2025-10 |
Nintedanib |
Not available |
Antineoplastic agents |
2021-10 |
Nintedanib esylate |
Not available |
Antineoplastic agents |
2023-06 |
Nintedanib esylate |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2024-05 |
Nintedanib esylate |
Marcan Pharmaceuticals Inc |
Antineoplastic agents |
2025-10 |
Nortriptyline hydrochloride |
Not available |
Psychoanaleptics |
2022-11 |
Nortriptyline hydrochloride |
Not available |
Psychoanaleptics |
2023-05 |
Obeticholic acid |
Apotex Inc |
Bile and liver therapy |
2024-09 |
Octreotide acetate |
Sterimax Inc |
Pituitary and hypothalamic hormones and analogues |
2025-05 |
Ofloxacin |
Mantra Pharma Inc. |
Ophthalmologicals |
2024-11 |
Olanzapine |
Teva Canada Limited |
Psycholeptics |
2024-08 |
Olanzapine |
Hikma Canada Limited |
Psycholeptics |
2025-07 |
Olaparib |
Zydus Lifesciences Limited |
Antineoplastic agents |
2025-07 |
Olaparib |
Cipla Limited |
Antineoplastic agents |
2025-10 |
Olaparib |
Natco Pharma (Canada) Inc |
Antineoplastic agents |
2025-10 |
Olopatadine hydrochloride |
Not available |
Ophthalmologicals |
2023-08 |
Ondansetron hydrochloride |
Not available |
Antiemetics and antinauseants |
2024-02 |
Oxcarbazepine |
JAMP Pharma Corporation |
Antiepileptics |
2024-05 |
Oxcarbazepine |
Odan Laboratories Ltd |
Antiepileptics |
2025-10 |
Oxcarbazepine |
Pharmaris Canada Inc |
Antiepileptics |
2025-12 |
Oxcarbazepine |
Mint Pharmaceuticals Inc |
Antiepileptics |
2026-02 |
Paclitaxel |
Accord Healthcare Inc |
Antineoplastic agents |
2024-09 |
Paclitaxel |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2024-12 |
Paclitaxel |
Natco Pharma (Canada) Inc |
Antineoplastic agents |
2026-02 |
Palbociclib |
Zydus Lifesciences Limited |
Antineoplastic agents |
2025-01 |
Palbociclib |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2025-05 |
Palbociclib |
Natco Pharma (Canada) Inc |
Antineoplastic agents |
2025-11 |
Paliperidone |
Not available |
Psycholeptics |
2020-09 |
Paliperidone |
Not available |
Psycholeptics |
2024-01 |
Paliperidone palmitate |
Not available |
Psycholeptics |
2020-09 |
Paliperidone palmitate |
Not available |
Psycholeptics |
2020-11 |
Paliperidone palmitate |
Not available |
Psycholeptics |
2021-06 |
Paliperidone palmitate |
Taro Pharmaceuticals Inc |
Psycholeptics |
2025-08 |
Pantoprazole magnesium |
Not available |
Drugs for acid related disorders |
2024-01 |
Pantoprazole sodium |
Baxter Corporation |
Drugs for acid related disorders |
2025-02 |
Pantoprazole sodium sesquihydrate |
Marcan Pharmaceuticals Inc |
Drugs for acid related disorders |
2025-05 |
Pantoprazole sodium sesquihydrate |
Axxelent Pharma Science Private Limited |
Drugs for acid related disorders |
2025-06 |
Pazopanib hydrochloride |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2024-05 |
Pemetrexed disodium |
Fresenius Kabi Canada Ltd |
Antineoplastic agents |
2025-07 |
Pemetrexed disodium hemipentahydrate, pemetrexed disodium heptahydrate |
Formative Pharma Inc. |
Antineoplastic agents |
2024-07 |
Perampanel |
Mint Pharmaceuticals Inc |
Antiepileptics |
2025-05 |
Perampanel |
Auro Pharma Inc |
Antiepileptics |
2025-11 |
Piperacillin sodium, tazobactam sodium |
Fresenius Kabi Canada Ltd |
Antibacterials for systemic use |
2024-08 |
Piperacillin sodium, tazobactam sodium |
Baxter Corporation |
Antibacterials for systemic use |
2026-01 |
Pomalidomide |
Not available |
Immunosuppressants |
2021-03 |
Ponatinib hydrochloride |
Apotex Inc |
Antineoplastic agents |
2024-06 |
Posaconazole |
MSN Labs Canada Inc. |
Antimycotics for systemic use |
2024-12 |
Posaconazole |
JAMP Pharma Corporation |
Antimycotics for systemic use |
2025-05 |
Pregabalin |
Mint Pharmaceuticals Inc |
Analgesics |
2024-12 |
Pregabalin |
Joint Stock Company Grindeks |
Analgesics |
2025-12 |
Progesterone |
JAMP Pharma Corporation |
Sex hormones and modulators of the genital system |
2026-01 |
Propranolol hydrochloride |
Mint Pharmaceuticals Inc |
Beta blocking agents |
2025-01 |
Prucalopride succinate |
Zydus Lifesciences Limited |
Drugs for constipation |
2025-01 |
Ramipril |
JAMP Pharma Corporation |
Agents acting on the renin-angiotensin system |
2026-01 |
Regorafenib |
Not available |
Antineoplastic agents |
2022-04 |
Regorafenib |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2024-11 |
Ribociclib succinate |
Natco Pharma (Canada) Inc |
Antineoplastic agents |
2024-04 |
Rifaximin |
Sandoz Canada Incorporated |
Antidiarrheals, intestinal anti-inflammatory/anti-infective agents |
2025-01 |
Risedronate sodium hemi-pentahydrate |
Jamp Pharma Corporation |
Drugs for treatment of bone diseases |
2025-11 |
Rivaroxaban |
Not available |
Antithrombotic agents |
2023-05 |
Rivaroxaban |
Accel Pharma Inc |
Antithrombotic agents |
2025-07 |
Rocuronium bromide |
Sterinova Inc |
Muscle relaxants |
2025-05 |
Rocuronium bromide |
Laboratoire Aguettant |
Muscle relaxants |
2025-09 |
Rocuronium bromide |
Sterimax Inc |
Muscle relaxants |
2026-01 |
Ropivacaine hydrochloride |
Hikma Canada Limited |
Anesthetics |
2025-02 |
Rupatadine fumarate |
Not available |
Antihistamines for systemic use |
2022-09 |
Rupatadine fumarate |
JAMP Pharma Corporation |
Antihistamines for systemic use |
2025-05 |
Ruxolitinib |
Pharmascience Inc |
Antineoplastic agents |
2025-06 |
Ruxolitinib hemifumarate |
Juno Pharmaceuticals Corp. |
Antineoplastic agents |
2025-08 |
Ruxolitinib hemifumarate |
Dr Reddys Laboratories Ltd |
Antineoplastic agents |
2025-10 |
Ruxolitinib hydrochloride |
MSN Labs Canada Inc. |
Antineoplastic agents |
2025-05 |
Ruxolitinib hydrochloride |
Teva Canada Limited |
Antineoplastic agents |
2025-09 |
Ruxolitinib mesylate |
Apotex Inc |
Antineoplastic agents |
2024-06 |
Ruxolitinib phosphate |
Not available |
Antineoplastic agents |
2023-04 |
Ruxolitinib phosphate |
Sun Pharma Canada Inc |
Antineoplastic agents |
2025-12 |
Ruxolitinib, ruxolitinib hemifumarate |
Ambicare Pharmaceuticals Inc. |
Antineoplastic agents |
2026-02 |
Sacubitril, valsartan |
Mylan Pharmaceuticals ULC |
Agents acting on the renin-angiotensin system |
2024-05 |
Sacubitril, valsartan |
Dr Reddys Laboratories Ltd |
Agents acting on the renin-angiotensin system |
2025-05 |
Sacubitril, valsartan |
Teva Canada Limited |
Agents acting on the renin-angiotensin system |
2025-05 |
Sacubitril, valsartan |
Alembic Pharmaceuticals Limited |
Agents acting on the renin-angiotensin system |
2025-06 |
Sacubitril, valsartan |
Apotex Inc |
Agents acting on the renin-angiotensin system |
2025-07 |
Sacubitril, valsartan |
MSN Labs Canada Inc. |
Agents acting on the renin-angiotensin system |
2025-07 |
Sacubitril, valsartan |
Zydus Lifesciences Limited |
Agents acting on the renin-angiotensin system |
2025-11 |
Sacubitril, valsartan |
Mint Pharmaceuticals Inc |
Agents acting on the renin-angiotensin system |
2026-01 |
Sapropterin dihydrochloride |
JAMP Pharma Corporation |
Other alimentary tract and metabolism products |
2024-11 |
Saxagliptin |
Not available |
Drugs used in diabetes |
2024-01 |
Saxagliptin hydrochloride |
Not available |
Drugs used in diabetes |
2023-09 |
Selexipag |
Not available |
Antithrombotic agents |
2022-08 |
Semaglutide |
Not available |
Drugs used in diabetes |
2024-02 |
Semaglutide |
Sandoz Canada Incorporated |
Drugs used in diabetes |
2024-11 |
Semaglutide |
Apotex Inc |
Drugs used in diabetes |
2025-01 |
Semaglutide |
Apotex Inc |
Drugs used in diabetes |
2025-04 |
Semaglutide |
Taro Pharmaceuticals Inc |
Drugs used in diabetes |
2025-06 |
Semaglutide |
Aspen Pharmacare Canada Inc. |
Drugs used in diabetes |
2025-08 |
Semaglutide |
Teva Canada Limited |
Drugs used in diabetes |
2025-08 |
Semaglutide |
Apotex Inc |
Drugs used in diabetes |
2025-11 |
Semaglutide |
Aspen Pharmacare Canada Inc. |
Drugs used in diabetes |
2026-02 |
Sertraline hydrochloride |
JAMP Pharma Corporation |
Psychoanaleptics |
2024-09 |
Sevelamer carbonate |
JAMP Pharma Corporation |
All other therapeutic products |
2025-08 |
Sevelamer carbonate |
Avir Pharma Inc |
All other therapeutic products |
2026-02 |
Sevelamer hydrochloride |
Not available |
All other therapeutic products |
2023-08 |
Sevelamer hydrochloride |
Waymade Canada Inc. |
All other therapeutic products |
2025-06 |
Sevelamer hydrochloride |
Avir Pharma Inc |
All other therapeutic products |
2025-11 |
Sildenafil citrate |
Not available |
Antihypertensives |
2023-07 |
Sildenafil citrate |
JAMP Pharma Corporation |
Urologicals |
2024-08 |
Silodosin |
Mint Pharmaceuticals Inc |
Urologicals |
2025-01 |
Spironolactone |
Not available |
Diuretics |
2024-03 |
Sufentanil citrate |
Juno Pharmaceuticals Corp. |
Anesthetics |
2025-08 |
Sugammadex sodium |
Not available |
All other therapeutic products |
2022-03 |
Sugammadex sodium |
Not available |
All other therapeutic products |
2023-10 |
Sugammadex sodium |
Not available |
All other therapeutic products |
2023-12 |
Sugammadex sodium |
Sterimax Inc |
All other therapeutic products |
2024-07 |
Sugammadex sodium |
Hikma Canada Limited |
All other therapeutic products |
2025-04 |
Sulfamethoxazole, trimethoprim |
Marcan Pharmaceuticals Inc |
Antibacterials for systemic use |
2025-08 |
Tacrolimus |
Not available |
Other dermatological preparations |
2021-03 |
Tacrolimus |
Not available |
Immunosuppressants |
2023-10 |
Tacrolimus |
JAMP Pharma Corporation |
Other dermatological preparations |
2024-12 |
Tadalafil |
Not available |
Urologicals |
2023-12 |
Tadalafil |
Not available |
Urologicals |
2024-01 |
Tamsulosin hydrochloride |
Not available |
Urologicals |
2024-02 |
Tamsulosin hydrochloride |
Pharmaris Canada Inc |
Urologicals |
2026-01 |
Temozolomide |
Marcan Pharmaceuticals Inc |
Antineoplastic agents |
2025-08 |
Tenofovir alafenamide fumarate |
Not available |
Antivirals for systemic use |
2022-01 |
Tenofovir alafenamide fumarate |
Not available |
Antivirals for systemic use |
2022-01 |
Tenofovir alafenamide fumarate |
Not available |
Antivirals for systemic use |
2022-07 |
Tenofovir alafenamide hemifumarate |
Ambicare Pharmaceuticals Inc. |
Antivirals for systemic use |
2025-11 |
Tenofovir disoproxil fumarate |
Generic Medical Partners Inc |
Antivirals for systemic use |
2024-06 |
Terazosin hydrochloride |
Mint Pharmaceuticals Inc |
Urologicals |
2025-07 |
Terbinafine hydrochloride |
Not available |
Antifungals for dermatological use |
2022-07 |
Teriflunomide |
Accel Pharma Inc |
Immunosuppressants |
2024-04 |
Teriflunomide |
Mint Pharmaceuticals Inc |
Immunosuppressants |
2024-08 |
Teriparatide |
Alembic Pharmaceuticals Limited |
Calcium homeostasis |
2026-01 |
Teriparatide acetate |
Not available |
Calcium homeostasis |
2023-09 |
Ticagrelor |
Not available |
Antithrombotic agents |
2023-09 |
Ticagrelor |
Not available |
Antithrombotic agents |
2024-02 |
Ticagrelor |
Accel Pharma Inc |
Antithrombotic agents |
2025-04 |
Ticagrelor |
Accord Healthcare Inc |
Antithrombotic agents |
2025-11 |
Tigecycline |
JAMP Pharma Corporation |
Antibacterials for systemic use |
2025-03 |
Tigecycline |
Marcan Pharmaceuticals Inc |
Antibacterials for systemic use |
2025-06 |
Timolol maleate, travoprost |
Not available |
Ophthalmologicals |
2023-05 |
Tipiracil hydrochloride, trifluridine |
Not available |
Antineoplastic agents |
2024-03 |
Tipiracil hydrochloride, trifluridine |
Pharmascience Inc |
Antineoplastic agents |
2024-05 |
Tofacitinib citrate |
Not available |
Immunosuppressants |
2023-10 |
Tofacitinib citrate |
Not available |
Immunosuppressants |
2024-02 |
Tofacitinib citrate |
MSN Labs Canada Inc. |
Immunosuppressants |
2024-06 |
Tofacitinib citrate |
Devatis Canada Inc. |
Immunosuppressants |
2025-09 |
Tofacitinib citrate |
Auro Pharma Inc |
Immunosuppressants |
2025-11 |
Tofacitinib citrate |
Zydus Lifesciences Limited |
Immunosuppressants |
2025-12 |
Tolvaptan |
Taro Pharmaceuticals Inc |
Diuretics |
2025-04 |
Tramadol hydrochloride |
Pharmaris Canada Inc |
Analgesics |
2025-08 |
Trametinib dimethyl sulfoxide |
Apotex Inc |
Antineoplastic agents |
2025-07 |
Tranexamic acid |
Fresenius Kabi Canada Ltd |
Antihemorrhagics |
2024-10 |
Travoprost |
Not available |
Ophthalmologicals |
2023-04 |
Travoprost |
Laboratoire Riva Inc |
Ophthalmologicals |
2025-10 |
Trifarotene |
Sun Pharma Canada Inc |
Anti-acne preparations |
2026-01 |
Valacyclovir hydrochloride |
Ambicare Pharmaceuticals Inc. |
Antivirals for systemic use |
2024-12 |
Valsartan |
JAMP Pharma Corporation |
Agents acting on the renin-angiotensin system |
2024-07 |
Varenicline tartrate |
JAMP Pharma Corporation |
Other nervous system drugs |
2025-10 |
Venlafaxine hydrochloride |
Teva Canada Limited |
Psychoanaleptics |
2025-07 |
Vilazodone hydrochloride |
Pharmascience Inc |
Psychoanaleptics |
2025-06 |
Vortioxetine hydrobromide |
JAMP Pharma Corporation |
Psychoanaleptics |
2024-08 |
Vortioxetine hydrobromide |
Laboratoire Riva Inc |
Psychoanaleptics |
2025-09 |
Vortioxetine hydrobromide |
Zydus Lifesciences Limited |
Psychoanaleptics |
2025-10 |
Vortioxetine hydrobromide |
Teva Canada Limited |
Psychoanaleptics |
2025-11 |
Vortioxetine hydrobromide |
Mantra Pharma Inc. |
Psychoanaleptics |
2025-11 |
Ziprasidone hydrochloride monohydrate |
JAMP Pharma Corporation |
Psycholeptics |
2025-05 |
Zoledronic acid |
JAMP Pharma Corporation |
Drugs for treatment of bone diseases |
2025-05 |
Zoledronic acid |
Formative Pharma Inc. |
Drugs for treatment of bone diseases |
2025-11 |
Zopiclone |
Not available |
Psycholeptics |
2023-11 |
Zopiclone |
Auro Pharma Inc |
Psycholeptics |
2024-07 |